Lenzumestrocel
- Generic Name
- Lenzumestrocel
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 6YY2MY21JA
Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS
Phase 1
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06676423
- Locations
- 🇰🇷
Hanyang university hospital, Seoul, Korea, Republic of
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS
Phase 3
Active, not recruiting
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Corestemchemon, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04745299
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Pusan National University Yangsan Hospital, Yangsan, Kyungsangnam-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath